Cancer patients should not take chemotherapy, radiotherapy or biological therapy (or should stop them) and follow the Tayebat system instead; 'we are against the word medicine'.
Original statement
خطر العلاج بيولوجي وو علاج كيماوي يا باشا احنا ضد كلمه دوا اصلا على وجه الارض
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Cancer patients should not take chemotherapy, radiotherapy or biological therapy (or should stop them) and follow the Tayebat system instead; 'we are against the word medicine'.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- السرطان ١ (Open source)
- Published
- 26 January 2025
- Timestamp
- 1:03:31 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Claimed mechanism
Cancer is the body's own plan; chemo harms own cells
- Claimed health effect
Avoid oncologic therapy
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Diverging source versions
ما فيش حاجه اسمها علاج كيماوي ياط كل افتراضات في السرطان غلط
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- هدفنا حياة بلا مرض مزعوم (Open source)
- Published
- 29 January 2025
- Timestamp
- 0:28:42 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
ناهد رشيدي من حالات سرطان الثدي اللي اتعفت معانا بفضل الله نائد رشيدي مشيت على نظامنا وبس وما اخدناش كيماوي وما اخدناش اشعاع وما استاصلناش ثدي ولا استاصلنا الورم
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (Open source)
- Published
- 26 March 2026
- Timestamp
- 0:24:59 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
امي ماشيه على النظام وعندها سرطان ثدي عامت عمليه ومش حابه تعمل كيماوي طبعا ما تعملش كيماوي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- زرع الكلي ： الحمد لله مناقشة حرة (Open source)
- Published
- 16 February 2025
- Timestamp
- 0:35:19 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
واحنا وقفنا يا جماعه الكيماوي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! مصير الهيموجلوبين (Open source)
- Published
- 13 May 2025
- Timestamp
- 0:24:04 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
واللي خد كيماوي ياخد يا باشا واللي ياخد اشعاع ياخد
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! النخاميه (Open source)
- Published
- 25 June 2025
- Timestamp
- 0:45:48 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
قالت ادوها كيماوي قامت واقفه مع الدكتوره خذت الكيماوي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- سرطان الرئةالحمد لله في ٥ شهور❤️❤️❤️❤️ (Open source)
- Published
- 26 February 2024
- Timestamp
- not available (transcript has no timings)
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Rejection of chemotherapy, radiotherapy and biologicals; presentation of patients who refused or stopped chemotherapy as successes.
2. What is demonstrably correct?
Elawady sometimes said patients decide themselves (P86iybRnOE4: those who want chemo may take it). End-of-life chemotherapy is often not beneficial (C-CHM-07). Side effects are real (C-CHM-01..06).
3. What is wrong or exaggerated?
In curable cancers, refusing chemotherapy, radiotherapy or surgery costs lives: alternative-only treatment HR 2.50 for death (breast cancer HR 5.68) (I-CHM-03); excess mortality with complementary medicine was mediated by refusal of conventional therapy (I-CHM-04); chemotherapy reduces breast-cancer mortality by about one-third (I-CHM-01); childhood ALL survival 90% (I-CHM-05). Even delays matter: in observational data, each 4-week delay (studied range about 4-16 weeks, in patients who were eventually treated) was associated with higher mortality (I-CHM-07); this concerns delay, not refusal. Individual reports of patients doing well without chemotherapy (e.g., after surgery) cannot show that the diet caused the outcome.
4. What remains unclear?
The outcomes of the specific patients mentioned in the videos are not verifiable.
5. Which studies support it?
None for replacing treatment. The only randomised diet trial found tested nutrition added to chemotherapy (elemental diet during chemotherapy for advanced pancreatic cancer: survival 21.4 vs 12.8 months, small single-centre trial; I-CHM-127).
6. Which studies contradict it?
I-CHM-01, I-CHM-02, I-CHM-03, I-CHM-04, I-CHM-05, I-CHM-07.
7. What applies to Germany and Europe?
Standard of care in Europe.
8. What is known about Egypt?
Standard of care in Egypt follows the same evidence. At Children's Cancer Hospital Egypt, 72.1% of 14,808 children treated for cancer were alive at 5 years, rising from 69.6% to 74.2% between 2007-12 and 2013-17 (I-CHM-125). In Southern Egypt, 60.5% of families of children with cancer used traditional or complementary remedies, 29% of users as an alternative, and 11.5% of users presented late (I-CHM-126).
9. What practical conclusion is appropriate?
Never replace indicated cancer treatment with a diet; nutrition questions should be discussed with the oncology team.
Assessment details
- Rationale for certainty of evidence
Randomised trials and large registries consistently show survival benefit of indicated treatment and excess mortality with refusal or delay.
- Source quality
Multiple machine transcripts; consistent pattern with some contrary statements.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: In patients with cancer, does avoiding or stopping chemotherapy, radiotherapy or biological therapy in favour of a diet (Tayebat system) lead to outcomes as good as standard treatment?
Research question in detail (PICO)
- Population
- Patients with cancer, especially curable cancers
- Intervention or exposure
- Diet/alternative approach instead of chemotherapy, radiotherapy or biological therapy
- Comparison
- Guideline-based treatment
- Geographic scope
- universal; Egyptian context considered
- Outcomes
- Overall survival
- Cancer-specific mortality
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Nutrition drink during chemotherapy for pancreatic cancer
Uemura S et al.. Clin Nutr ESPEN 2026 · PMID 41794391 · DOI 10.1016/j.clnesp.2026.103106 Randomised controlled trialabstract checkednewly addedSmall RCT: an elemental diet added to chemotherapy improved response and survival in advanced pancreatic cancer.
- Actual result
- OS 21.4 vs 12.8 months (HR 0.55, 0.31-0.98)
- Methodological quality
- low (60 patients, single centre)
- Relevance
- indirect: diet with, not instead of, chemotherapy
- Limitations
- Small; unreplicated
What speaks against the claim?
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145 Cohort studyabstract checkedPatients with curable cancers who used alternative medicine instead of conventional treatment had higher mortality.
- Actual result
- HR 2.50 (1.88-3.27); breast HR 5.68
- Methodological quality
- moderate (registry cohort)
- Relevance
- direct
- Limitations
- Observational; few alternative users
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4 Meta-analysisfull text checkednewly addedChemotherapy reduces recurrence and breast-cancer death in randomised IPD.
- Actual result
- Recurrence RR 0.86; up to 8.7 points fewer recurrences at 10 years
- Methodological quality
- high
- Relevance
- direct
- Limitations
- None material
Chemotherapy after pancreatic cancer surgery
Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201 Randomised controlled trialabstract checkednewly addedChemotherapy after pancreatic surgery doubled 5-year survival versus observation.
- Actual result
- 20.7% vs 10.4%
- Methodological quality
- high (RCT)
- Relevance
- direct
- Limitations
- Open-label
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Replacing indicated chemotherapy, radiotherapy or biological therapy with a diet increases the risk of death; nutrition can support patients alongside treatment.
Why some studies weigh more
Randomised trials of treatment vs no treatment and registry data on alternative-only use; no trial tested any diet as a replacement.
Is a causal relationship established? Yes, established Randomised treatment benefit; consistent excess mortality with refusal.
Remaining uncertainty
None material for the verdict.
Justified conclusion
False and potentially life-threatening.
Why do studies seem to disagree?
Nutrition trials (I-CHM-127) and treatment trials do not conflict: nutrition was tested as an addition to chemotherapy.
Does this depend on the country?
- General biological effects
- Universal clinical evidence.
- Eating habits
- Alternative and nutritional remedies are widely used by Egyptian families of children with cancer, sometimes instead of treatment and with delays (I-CHM-126).
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Egyptian childhood cancer 5-year survival with standard treatment 72.1% and rising (I-CHM-125).
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Absolute difference – 5-y OS 82.2% vs 86.6% (4.4 points) with complementary medicine; HR attenuated after adjusting for refusal (mediation) recalculated
- Precision – HR 0.55 (0.31-0.98): upper bound near 1; small trial likely overestimates effect not recalculable from the published data
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Mortality when indicated treatment is replaced by diet/alternative care
- Starting level
- high (randomised trials)
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- NICE: Early and locally advanced breast cancer: diagnosis and management (NG101) (2018, last updated 14 April 2025) · Original publication
Offer whole-breast radiotherapy after breast-conserving surgery with clear margins; offer postmastectomy radiotherapy for node-positive disease or involved margins; do not offer postmastectomy radiotherapy to people at low risk of local recurrence; where adjuvant chemotherapy is indicated, offer a regimen containing a taxane and an anthracycline and discuss benefits and risks. - WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · Original publication
Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer. - NCI: Chemotherapy to Treat Cancer (2026 (fetched 2026-10-26)) · Original publication
Chemotherapy can be used to cure cancer, lessen the chance it will return, or stop or slow its growth, and to ease symptoms; it also harms fast-growing healthy cells, causing side effects.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed | 26 October 2026 | (diet[ti] OR dietary[ti] OR nutrition[ti] OR "ketogenic"[ti]) AND (cancer[ti] OR tumor[ti] OR tumour[ti]) AND (survival[ti] OR remission[ti]) AND randomized controlled trial[pt] | supporting evidence | 16 | |
| PubMed | 26 October 2026 | ("alternative medicine"[ti] OR "alternative therapy"[ti] OR "unconventional"[ti]) AND cancer[ti] AND (survival[ti] OR mortality[ti]) AND 2010:2026[dp] | both directions | 9 | |
| Europe PMC | 26 October 2026 | (TITLE:"alternative medicine" OR TITLE:"complementary medicine" OR TITLE:"herbal") AND TITLE:"cancer" AND (Egypt OR Egyptian OR Arab OR "Saudi" OR "Middle East") AND PUB_YEAR:[2010 TO 2026] | both directions | 89 | |
| Europe PMC | 26 October 2026 | (TITLE:"abandonment" OR TITLE:"refusal") AND (Egypt OR Egyptian) AND (cancer OR leukemia OR leukaemia) | contradicting evidence | 10 | |
| Europe PMC | 26 October 2026 | (TITLE:"survival") AND (TITLE:"breast cancer" OR TITLE:"childhood cancer" OR TITLE:"leukemia") AND TITLE:"Egypt" AND PUB_YEAR:[2015 TO 2026] | contradicting evidence | 4 | |
| PubMed | 26 October 2026 | "Early Breast Cancer Trialists Collaborative Group"[Corporate Author] AND Lancet[ta] AND 2012:2026[dp] | contradicting evidence | 12 | |
| Europe PMC | 26 October 2026 | TITLE:"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer" | contradicting evidence | 1 |
Open questions
Outcomes of Egyptian patients who follow diet-only approaches (no data found).
How deeply was this checked?
12 linked studies: 5 checked in full text (3 of them with a structured risk-of-bias assessment), 7 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: False (high)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: False (high)
New randomised and Egyptian data reinforce the verdict; the one diet trial found supports diet as an addition, not a replacement.
New sources: I-CHM-101 I-CHM-102 I-CHM-120 I-CHM-125 I-CHM-126 I-CHM-127
In plain language
In several videos Dr. Diaa spoke against chemotherapy, radiotherapy and biological drugs, and presented patients who stopped chemotherapy as successes. The scientific evidence is clear: for many cancers these treatments greatly increase the chance of survival. People who replace them with alternative methods die much more often, for breast cancer about five times as often in one large study. Individual stories cannot show that a diet cured a cancer.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (10)
-
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyIn 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Refusing chemo forgoes ~1/3 mortality reduction
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare chemotherapy regimens and no chemotherapy.
- How was the study done?
IPD meta-analysis of RCTs.
- How many people, animals or samples were studied?
~100,000 women.
- What was actually found?
~1/3 lower breast-cancer mortality.
- How large was the observed effect?
RR 0.64-0.78 vs none.
- What do the results mean in everyday life?
For many women, chemotherapy substantially raises the chance of survival.
- What are the study's limitations?
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- What does it say about Elawady's specific claim?
Contradicts claims that chemotherapy is useless.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit without risk assessment.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyRecurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
Refusing RT increases recurrence
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure radiotherapy benefit.
- How was the study done?
IPD meta-analysis.
- How many people, animals or samples were studied?
10,801 women.
- What was actually found?
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- How large was the observed effect?
-15.7% recurrence; -3.8% death.
- What do the results mean in everyday life?
Radiotherapy markedly lowers the chance the cancer returns.
- What are the study's limitations?
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit size without risk factors.
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145Cohort studyindependent cross-checkabstract checked★ key studyRisk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
AM only: HR 2.50
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare AM-only vs conventional treatment.
- How was the study done?
Matched registry cohort.
- How many people, animals or samples were studied?
840 matched patients.
- What was actually found?
HR 2.50 for death.
- How large was the observed effect?
HR 5.68 breast cancer.
- What do the results mean in everyday life?
Replacing cancer treatment with alternatives is dangerous.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusing therapy.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Effects of complementary approaches used alongside treatment.
-
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487Cohort studyindependent cross-checkabstract checked★ key studyUsers of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.
Refusal mediates excess mortality
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Study CM and survival.
- How was the study done?
Registry cohort.
- How many people, animals or samples were studied?
258 vs 1,032.
- What was actually found?
HR 2.08; explained by refusal.
- How large was the observed effect?
5-y OS 82.2% vs 86.6%.
- What do the results mean in everyday life?
Diet or other approaches alongside treatment are not the problem; replacing treatment is.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusal advice.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Causal effect of any single CM.
-
About 9 in 10 children with leukaemia now survive
Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018Cohort studyindependent cross-checkabstract checked★ key study5-year survival in childhood ALL rose to 90.4% by 2000-2005.
Cure with chemo
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track ALL survival.
- How was the study done?
Trial cohort analysis.
- How many people, animals or samples were studied?
21,626.
- What was actually found?
83.7% -> 90.4%.
- How large was the observed effect?
+6.7 points.
- What do the results mean in everyday life?
Childhood leukaemia is usually curable with treatment.
- What are the study's limitations?
Trial patients.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Survival outside trials.
-
Each month of delay in cancer treatment raises the risk of death
Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyFor example, every 4-week delay of breast surgery was linked to 8% higher mortality.
Delay raises mortality
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Quantify harm from delay.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
1.27 million patients.
- What was actually found?
Higher mortality with delay.
- How large was the observed effect?
HR 1.06-1.08 per 4 weeks (surgery).
- What do the results mean in everyday life?
Do not postpone recommended treatment.
- What are the study's limitations?
Observational, mostly US registry data; valid only for delays of about 4-16 weeks; not suitable for predicting an individual's risk.
- What does it say about Elawady's specific claim?
Safety.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
The effect of delays longer than 16 weeks or of refusing treatment altogether; the effect for every cancer type; proof of causation.
-
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4Meta-analysisindependent cross-checkfull text checked★ key studyAnthracycline-taxane chemotherapy lowered recurrence and breast-cancer death; it caused about one extra leukaemia per 700 women and no measurable excess heart deaths within about 5 years.
Randomised evidence of survival benefit from chemotherapy.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Weigh benefits and risks of anthracycline-containing chemotherapy
- How was the study done?
Pooled individual data from randomised trials
- How many people, animals or samples were studied?
18,103 women in the main comparison; about 100,000 overall
- What was actually found?
Fewer recurrences (RR 0.86) and fewer breast-cancer deaths; AML 0.18% vs 0.03%
- How large was the observed effect?
10-year recurrence 16.4% vs 18.9%; up to 8.7 points fewer recurrences with concurrent anthracycline
- What do the results mean in everyday life?
For every leukaemia caused, roughly 18 recurrences are prevented in this data set
- What are the study's limitations?
Short follow-up for heart effects; high-risk heart patients often excluded
- What does it say about Elawady's specific claim?
Harms of chemotherapy are real (AML) but small compared with the benefit; this contradicts the idea that harms outweigh benefits
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot quantify heart failure 15-20 years after treatment
-
Radiotherapy after breast removal: 20-year results of 22 trials
EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8Meta-analysisindependent cross-checkfull text checked★ key studyIn women with cancer in the lymph nodes, radiotherapy prevented about 1 in 10 recurrences and about 1 in 12 breast-cancer deaths; in low-risk women with old techniques it did more harm than good.
Randomised survival benefit of radiotherapy.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether radiotherapy after mastectomy saves lives
- How was the study done?
Pooled individual data from 22 randomised trials
- How many people, animals or samples were studied?
8135 women, 1964-86
- What was actually found?
Benefit in node-positive disease; overall mortality increase in node-negative women after full axillary surgery
- How large was the observed effect?
pN+: recurrence 62.5% -> 51.9%; breast-cancer death 66.4% -> 58.3%
- What do the results mean in everyday life?
Radiotherapy helps when recurrence risk is substantial and can harm when it is low
- What are the study's limitations?
Old techniques; modern doses are lower
- What does it say about Elawady's specific claim?
Contradicts blanket claims that radiotherapy does more harm than good; supports careful selection
- Do the results apply to Germany and Europe?
Moderate to high
- What can explicitly not be concluded from this study?
Cannot give exact absolute benefits for today's patients
-
Chemotherapy after pancreatic cancer surgery
Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201Randomised controlled trialindependent cross-checkabstract checked★ key studyChemotherapy after surgery doubled 5-year survival (21% vs 10%) compared with surgery alone.
Randomised survival benefit of chemotherapy.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test chemotherapy after pancreatic surgery
- How was the study done?
Randomised trial
- How many people, animals or samples were studied?
354 patients
- What was actually found?
Longer survival with chemotherapy
- How large was the observed effect?
5-y OS 20.7% vs 10.4%
- What do the results mean in everyday life?
Even in a hard-to-treat cancer, chemotherapy saves some lives
- What are the study's limitations?
Open-label
- What does it say about Elawady's specific claim?
Contradicts 'chemo cannot work because of fibrosis'
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot promise cure for an individual
-
Childhood cancer survival in Egypt
Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321Cohort studyindependent cross-checkabstract checked★ key studyAt Egypt's main children's cancer hospital, 72% of children were alive 5 years after diagnosis, and survival improved over time.
In Egypt, most children treated with standard therapy survive 5 years.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure Egyptian childhood cancer survival
- How was the study done?
Hospital cohort
- How many people, animals or samples were studied?
14,808 children
- What was actually found?
Survival rising
- How large was the observed effect?
5-y OS 72.1%; 69.6% -> 74.2%
- What do the results mean in everyday life?
Treatment cures most children in Egypt too
- What are the study's limitations?
Single hospital; no untreated group
- What does it say about Elawady's specific claim?
Contradicts the futility claim
- Do the results apply to Germany and Europe?
High (Egyptian data)
- What can explicitly not be concluded from this study?
Cannot isolate the effect of each treatment
No study in this group is marked as key.
Studies with mixed or unclear results (2)
-
Traditional medicine use by children with cancer in Southern Egypt
Farrag A et al.. Pediatr Blood Cancer 2024 · PMID 39289855 · DOI 10.1002/pbc.31326Cross-sectional studyindependent cross-checkabstract checked60% of families used traditional or complementary remedies; some used them instead of treatment and some came late.
Context only: alternative and nutritional approaches are used in Egypt, sometimes instead of treatment and with delays; no outcome data.
Does the study support the specific claim? Unclear · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Describe traditional medicine use
- How was the study done?
Interview survey
- How many people, animals or samples were studied?
86 children
- What was actually found?
Common use; some delays
- How large was the observed effect?
60.5% use; 11.5% of users delayed
- What do the results mean in everyday life?
Doctors should ask families about remedies
- What are the study's limitations?
Small, no outcomes
- What does it say about Elawady's specific claim?
Shows the risk is real in Egypt
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot show the effect on survival
-
Nutrition drink during chemotherapy for pancreatic cancer
Uemura S et al.. Clin Nutr ESPEN 2026 · PMID 41794391 · DOI 10.1016/j.clnesp.2026.103106Randomised controlled trialindependent cross-checkabstract checkedIn a small trial, patients who took a special nutrition formula during chemotherapy lived longer (21.4 vs 12.8 months).
Supports the part that nutrition matters; contradicts replacing treatment, because the benefit was seen with diet added to chemotherapy.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test nutritional support during chemotherapy
- How was the study done?
Small randomised trial
- How many people, animals or samples were studied?
60 patients
- What was actually found?
Better nutrition, response and survival
- How large was the observed effect?
OS HR 0.55 (0.31-0.98)
- What do the results mean in everyday life?
Good nutrition may help treatment work; it goes with treatment, not instead of it
- What are the study's limitations?
Very small, needs confirmation
- What does it say about Elawady's specific claim?
Supports nutrition alongside treatment, not instead of it
- Do the results apply to Germany and Europe?
Moderate
- What can explicitly not be concluded from this study?
Cannot show diet can replace chemotherapy
No study in this group is marked as key.
Regional context
Germany / EU
Standard of care in Europe.
Egypt
Standard of care in Egypt follows the same evidence. At Children's Cancer Hospital Egypt, 72.1% of 14,808 children treated for cancer were alive at 5 years, rising from 69.6% to 74.2% between 2007-12 and 2013-17 (I-CHM-125). In Southern Egypt, 60.5% of families of children with cancer used traditional or complementary remedies, 29% of users as an alternative, and 11.5% of users presented late (I-CHM-126).
What applies in my country?
General scientific assessment
False This claim is false: no study shows that a diet can replace chemotherapy, radiotherapy or biological therapy, while randomised trials show these treatments prevent deaths and alternative-only care is associated with markedly higher mortality; nutrition can help alongside treatment, not instead of it.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
- Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
- Mortality due to cancer treatment delay: systematic review and meta-analysis.. Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.. EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8
- Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.. Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201
- Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt.. Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321
- Family strategies for managing childhood cancer: Using traditional and complementary medicine in Southern Egypt.. Farrag A et al.. Pediatr Blood Cancer 2024 · PMID 39289855 · DOI 10.1002/pbc.31326
- Early elemental diet supplementation during chemotherapy improves treatment response and survival in advanced pancreatic cancer: A single-center randomized controlled trial.. Uemura S et al.. Clin Nutr ESPEN 2026 · PMID 41794391 · DOI 10.1016/j.clnesp.2026.103106